Sucralfate

Sucralfate is prescribed to treat:

• Stomach and duodenal ulcers • Various related conditions in the gastrointestinal category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Sucralfate (Carafate) is a mucosal protective agent used for duodenal and gastric ulcers, stress ulcer prophylaxis, and a range of mucosal injuries including radiation proctitis and oral mucositis. It does not reduce acid — it works by physically coating damaged tissue, which makes it mechanistically unlike every other ulcer treatment.

Mechanism of Action

Sucralfate is a complex of sucrose octasulfate and aluminium hydroxide. In the acidic environment of the stomach it polymerises into a viscous, sticky paste that binds selectively to exposed proteins at sites of mucosal ulceration or erosion.

The resulting barrier is adherent and can persist for hours, physically shielding damaged tissue from acid, pepsin, and bile while healing proceeds. Binding is far greater at injured sites than at intact mucosa, which is why it concentrates where it is needed.

Beyond the physical barrier, sucralfate stimulates local prostaglandin and bicarbonate secretion, increases mucus production, and binds epidermal growth factor at the ulcer base, concentrating a healing signal where tissue repair is required.

Two consequences follow from the mechanism. It requires an acidic environment to activate, so co-administration with a proton pump inhibitor such as omeprazole or an antacid reduces its effectiveness — doses should be separated. And because it works by contact, it must reach the damaged tissue, which is why it is taken on an empty stomach, an hour before meals, when food will not be in the way.

Systemic absorption is minimal, which is the source of its excellent safety profile and its main limitation: it does nothing that is not local.

Clinical Use

Sucralfate's role has narrowed considerably. For duodenal and gastric ulcers, proton pump inhibitors heal faster and more reliably, and H. pylori eradication addresses the cause in most cases. Sucralfate is now used mainly where acid suppression is unsuitable or where a local protective effect is specifically wanted.

Where it remains genuinely valuable is in mucosal injury outside the stomach. As a suspension it is used for radiation proctitis, for oral mucositis after chemotherapy or radiation, and for oesophagitis — applications that exploit its coating action on damaged mucosa anywhere it can be delivered.

It is also used in bile reflux, where acid suppression is logically unhelpful because bile rather than acid is the irritant, and sucralfate binds bile salts directly.

Its safety profile makes it attractive in pregnancy, where minimal absorption is a genuine advantage over systemic agents.

The dosing schedule is its main practical drawback: four times daily on an empty stomach, an hour before meals and at bedtime, is demanding and adherence suffers accordingly. Where a once-daily PPI would work equally well, it usually wins on that basis alone. Our gastrointestinal team manages ulcer disease that is not responding.

The Binding Problem

Sucralfate's stickiness is not selective about what it binds, and it substantially reduces absorption of many other drugs taken at the same time.

Affected drugs include levothyroxine, fluoroquinolones such as ciprofloxacin and levofloxacin, digoxin, phenytoin, tetracyclines including doxycycline, and warfarin.

The consequences are real. A patient on levothyroxine whose TSH becomes erratic, or one on warfarin whose INR drifts, may be experiencing a sucralfate interaction that nobody has connected — precisely because sucralfate feels like an innocuous coating agent rather than a systemically active drug.

The rule is to separate sucralfate from other oral medications by at least two hours. This compounds the scheduling difficulty in a patient already taking several drugs, and it is a legitimate reason to choose a different agent.

Aluminium is absorbed in small amounts, which is not significant in normal kidney function but accumulates in chronic kidney disease and dialysis, where aluminium toxicity — encephalopathy, osteomalacia, anemia — is a genuine concern. The MedlinePlus sucralfate entry covers prescribing detail.

Monitoring and Follow-Up

No routine laboratory monitoring is required in normal kidney function. In significant renal impairment, aluminium accumulation warrants caution and generally argues for a different agent.

Constipation is the most common adverse effect, reflecting the aluminium content, and is usually mild.

The more important monitoring is whether the ulcer or mucosal injury is healing and whether the underlying cause has been addressed. Sucralfate coats an ulcer; it does not eradicate H. pylori, does not stop an NSAID from causing further injury, and does not treat malignancy.

Alarm features — difficulty or pain on swallowing, unintended weight loss, gastrointestinal bleeding, persistent vomiting, or iron deficiency anemia — require endoscopy rather than continued empiric treatment.

Special Populations

In pregnancy, sucralfate's minimal systemic absorption makes it a reasonable choice for reflux and ulcer symptoms when non-drug measures are insufficient, and it is compatible with breastfeeding.

In chronic kidney disease and dialysis, aluminium accumulation is the limiting concern and sucralfate is generally avoided. In older adults, the four-times-daily schedule and the extensive binding interactions both weigh against it in polypharmacy.

Tablets can be dissolved in water for patients with swallowing difficulty, and a suspension exists. Patients with diabetes should be aware the suspension contains sorbitol.

One further use is worth noting because it falls outside the gastrointestinal tract entirely. Sucralfate suspension is used as a mouthwash for oral mucositis during chemotherapy and radiation, and compounded as a paste or cream for painful skin and mucosal ulceration — including radiation dermatitis and some chronic wounds. The evidence in these settings is mixed and largely from small studies, but the mechanism translates plausibly and the safety profile makes a trial reasonable where standard options have failed. The NIDDK peptic ulcer resource covers the primary indication.

When to Contact Your Doctor

Seek prompt evaluation for black or tarry stools, vomiting blood or coffee-ground material, severe abdominal pain, difficulty swallowing, or unintended weight loss — none of these should be managed with a coating agent.

Report constipation that is troublesome. Report symptoms that are not improving after an adequate course, which usually means the underlying cause has not been addressed.

If you take other medications, confirm the timing — separating them from sucralfate by two hours matters, and getting this wrong quietly reduces the effectiveness of the other drug rather than of the sucralfate.

To review ulcer treatment, address symptoms that are not settling, or check medication timing, contact us or schedule a visit.